ProPhase Labs Q1 2024 GAAP EPS $(0.07) Beats $(0.18) Estimate, Sales $3.634M Miss $9.860M Estimate
Portfolio Pulse from Benzinga Newsdesk
ProPhase Labs (NASDAQ:PRPH) reported Q1 2024 earnings with a GAAP EPS of $(0.07), surpassing the $(0.18) estimate, but missed sales estimates with $3.634M against the expected $9.860M. This represents an 81.17% decrease in sales compared to the same period last year.

May 09, 2024 | 12:02 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
ProPhase Labs reported better-than-expected Q1 2024 EPS but missed on sales, with a significant year-over-year decrease.
While the EPS beat may provide a short-term positive sentiment, the significant miss on sales and the sharp year-over-year decline could raise concerns about the company's revenue growth and operational efficiency. The mixed results could lead to neutral market reaction as investors weigh the positive EPS against the negative sales performance.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100